Blaze Bioscience to Present Tumor Paint BLZ-100 at SPIE Photonics West Conference

SEATTLE--()--Blaze Bioscience, Inc., the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that Heather Franklin, Blaze’s President and CEO, will present the Company’s first Tumor Paint product—BLZ-100—at the SPIE Photonics West Conference on February 13 and 14, 2016. Tumor Paint BLZ-100 will be featured during the BiOS Hot Topics plenary session on the latest technical breakthroughs and promising technologies. The conference is being held in San Francisco, California.

Presentation details

BiOS Hot Topics

Date: Saturday February 13, 2016
Time: 8:45-8:55 p.m. Pacific Time
Location: The Moscone Center, Room 3022 (West Level 3)
Paper number: 9696-500 - “Targeted Fluorescence Image-Guided Surgery”
 

Preclinical Applications and Clinical Translation II

Date: Sunday February 14, 2016
Time: 11:00-11:30 a.m.
Location: The Moscone Center, Room 3006 (West Level 3)
Paper number: 9696-29 - “BLZ-100 tumor fluorescent reporter” (invited paper)

About BLZ-100

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide) and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, potentially enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types. BLZ-100 is an investigational agent currently in multiple Phase 1 proof-of-concept clinical studies to evaluate the safety and imaging characteristics of BLZ-100 in solid tumors, including brain, breast, lung, prostate, colorectal, sarcoma, and skin cancer. More details about on-going trials are available at www.blazebioscience.com or www.clinicaltrials.gov.

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former member of the executive management team at ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide-based therapeutics. Surgery is first-line therapy for most solid tumor cancers and Tumor Paint products have the potential to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research Center to discover and develop products based on knottin peptides as part of the Optides platform. This program extends the expertise gained in developing the Tumor Paint platform to optimized knottin peptides for therapeutic and imaging applications. For additional information, please visit www.blazebioscience.com.

Contacts

Media-
Blaze Bioscience, Inc.
Lauren Nelson, 206-535-8144
lauren.nelson@blazebioscience.com
or
Investor Relations-
SOS Communications LLC
Susan Specht Oram, 360-535-3035
spechtoram@gmail.com

Release Summary

Blaze Bioscience to present Tumor Paint BLZ-100 at SPIE Photonics West Conference.

Contacts

Media-
Blaze Bioscience, Inc.
Lauren Nelson, 206-535-8144
lauren.nelson@blazebioscience.com
or
Investor Relations-
SOS Communications LLC
Susan Specht Oram, 360-535-3035
spechtoram@gmail.com